We are live on ! Find out more
LYEL icon

Lyell Immunopharma
LYEL

93 hedge funds and large institutions have $823M invested in Lyell Immunopharma in 2022 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 34 increasing their positions, 15 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

450% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 4

127% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 15

25% more funds holding in top 10

Funds holding in top 10: 4 → 5 (+1)

24% more funds holding

Funds holding: 75 → 93 (+18)

20% more capital invested

Capital invested by funds: $689M → $823M (+$135M)

0.12% more ownership

Funds ownership: 2.15% → 2.27% (+0.12%)

Holders
93
Holders Change
+18
Holders Change %
+24%
% of All Funds
1.6%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.09%
New
22
Increased
34
Reduced
15
Closed
4
Calls
$15K
Puts
–
Net Calls
+$15K
Net Calls Change
-$3.86M

Top Buyers

1
State Street
State Street
Massachusetts
+$18.8M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$12M
3
BlackRock
BlackRock
New York
+$11.7M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$7.27M
5
Northern Trust
Northern Trust
Illinois
+$5.65M

Top Sellers

1
FCMI
Foresite Capital Management IV
California
-$22.2M
2
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University
California
-$10.7M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$1.09M
4
SG Americas Securities
SG Americas Securities
New York
-$275K
5
Victory Capital Management
Victory Capital Management
Texas
-$151K
Name Holding Trade Value Shares
Change 		Change in
Stake
MM
1
MWG Management
British Virgin Islands
$148M – – –
A
2
Apoletto
British Virgin Islands
$111M – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$90.9M +$12M +88,831 +17%
BlackRock
4
BlackRock
New York
$86M +$11.7M +86,369 +17%
FCMI
5
Foresite Capital Management IV
California
$73.3M -$22.2M -164,109 -25%
AI
6
Alphabet Inc
California
$43M – – –
State Street
7
State Street
Massachusetts
$39.4M +$18.8M +139,196 +107%
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
$38.9M -$141K -1,045 -0.4%
Fidelity Investments
9
Fidelity Investments
Massachusetts
$24.1M +$3.34M +24,654 +18%
MCMU
10
MIC Capital Management (UK)
United Kingdom
$22.4M – – –
HH
11
HSG Holding
Hong Kong
$22.3M – – –
Geode Capital Management
12
Geode Capital Management
Massachusetts
$21.6M +$7.27M +53,729 +57%
Northern Trust
13
Northern Trust
Illinois
$14.9M +$5.65M +41,722 +69%
Charles Schwab
14
Charles Schwab
California
$8.15M +$4.22M +31,146 +127%
Massachusetts Financial Services
15
Massachusetts Financial Services
Massachusetts
$7.77M +$486K +3,590 +7%
Baillie Gifford & Co
16
Baillie Gifford & Co
United Kingdom
$5.54M +$321K +2,372 +7%
AG
17
Artal Group
Luxembourg
$5.13M – – –
Bank of New York Mellon
18
Bank of New York Mellon
New York
$4.83M +$741K +5,475 +20%
Canada Pension Plan Investment Board
19
Canada Pension Plan Investment Board
Ontario, Canada
$4.31M – – –
N
20
Nuveen
North Carolina
$4.28M -$95.7K -707 -2%
JP Morgan Chase
21
JP Morgan Chase
New York
$3.81M -$48.6K -359 -1%
Federated Hermes
22
Federated Hermes
Pennsylvania
$3.76M – – –
Morgan Stanley
23
Morgan Stanley
New York
$3.04M +$1.34M +9,909 +91%
Goldman Sachs
24
Goldman Sachs
New York
$2.82M +$1.24M +9,191 +91%
Invesco
25
Invesco
Georgia
$2.28M +$1.73M +12,744 +454%
1
2 3 4

LYEL Hedge Fund Activity: Q3 2022 in Review

93 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Lyell Immunopharma (LYEL) for Q3 2022, worth a combined $823M — up 20% from $689M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new LYEL positions and 4 closed out — a net gain of 18 holders — while 34 added to existing stakes and 15 trimmed.

The largest buyer was State Street, adding an estimated $18.8M. The largest seller was Foresite Capital Management IV, cutting an estimated $22.2M.

  • 93 institutional investors held Lyell Immunopharma (LYEL) as of Q3 2022, up from 75 in Q2 2022.
  • Funds reported $823M of Lyell Immunopharma stock for Q3 2022, up 20% quarter-over-quarter.
  • 22 funds opened new Lyell Immunopharma positions in Q3 2022 and 4 closed out, a net change of +18 holders.
  • The largest Lyell Immunopharma buyer in Q3 2022 was State Street, an estimated $18.8M added.
  • The largest Lyell Immunopharma seller in Q3 2022 was Foresite Capital Management IV, an estimated $22.2M sold.

Based on aggregated 13F filings for Q3 2022.